Incretin-based Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The incretin-based drugs market is segmented by Drug Type (Glucagon, like Peptide-1 (GLP-1) Receptor Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors), Route of Administration, Distribution Channel, and Geography

Market Snapshot

incretin based drugs market Size
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.2 %
incretin based drugs market Key players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The incretin-based drugs market is anticipated to register a CAGR of about 5.2% during the forecast period.

Certain factors driving the market's growth include the increasing prevalence of obesity and diabetes, increasing awareness regarding health, and R&D activities.

The global diabetic population increased significantly in the past decade. Several reports and surveys documented the drastic increase in the diabetic population, based on the changing lifestyle and habits. For instance, according to the British Diabetic Association, it is estimated that almost 3.7 million people are living with diabetes in the United Kingdom and the number doubled in the past two decades. Moreover, around 12.3 million people are at an increased risk of Type-2 diabetes in the United Kingdom. Obesity is the leading cause in most of the cases.

· The two most recently approved classes of therapeutic agents for the treatment of type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists and dipeptidyl peptidase-4 inhibitors (DPP-4i), exert their actions through potentiation of incretin receptor signaling. Incretins are gut-derived hormones, principally GLP-1 and glucose-dependent insulinotropic peptide (GIP), that are secreted at low basal levels in the fasting state. The ongoing research and development activities on incretin-based drugs are expected to drive the market's growth over the forecast period.

Scope of the Report

Incretin-based treatments control post-meal glucagon and help reduce the post-meal blood sugars. These medicines also refer to blood sugar normalizing medications or euglycemic, i.e. drugs that help retain the blood sugar to the normal range. The incretin-based medicines are available in two families of medicines, i.e. DPP-4 Inhibitors and GLP-1 analogs.

By Drug Type
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
By Route of Administration
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Glucagon-like Peptide-1 (GLP-1) Receptor Agonists Holds Significant Share in the Global Incretin-Based Drugs Market

The incretin system has become an important target in the treatment of Type-2 diabetes and the most recent understanding of this deficit suggests that it relates to the deterioration of the GLP-1 effect, with impaired capacity to secrete insulin, increasing insulin resistance, and hyperglycemia, perhaps leading to a decrease in GLP-1 receptor expression and resulting in GLP-1 resistance. 

Hence, in the past few years, the demand for glucagon-like peptide 1 (GLP-1) increased for its glucose-lowering effects. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with Type-2 diabetes. It might be augmented by the administration of GLP-1 receptor agonists.

The GLP-1 receptor agonists currently approved in the United States for the treatment of Type-2 diabetes include exenatide (administered twice daily), liraglutide and lixisenatide (administered once daily), and the once-weekly agents' exenatide extended-release, albiglutide, and dulaglutide.

incretin based drugs market Trends

North America Dominates the Global Incretin-Based Drugs Market

In the past decade, the prevalence of diabetes in North America increased. People with diabetes need proper and effective therapeutics. Hence, the demand for incretin-based drugs increased significantly in the region.

In Canada, the prevalence of diabetes among adults is 10.2% and about 3.6 million patients were suffering from diabetes in 2017. The number of patients suffering from Type-2 diabetes is 94.4% of the diabetic population.

Furthermore, the prevalence of diabetes is increasing among all age groups, which can be attributed to the increasing obese population, along with unhealthy diets and sedentary lifestyles of people.

incretin based drugs market Growth rate

Competitive Landscape

The incretin-based drugs market is competitive and consists of a few major players. Companies, like AstraZeneca, Boehringer Ingelheim Pharmaceuticals Inc., Eli Lilly, GlaxoSmithKline PLC., Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, and Sanofi SA, among others, hold the major share in the market.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Obsesity and Diabetes

      2. 4.2.2 Growing Awareness and R&D Activities

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Reimbursement

      2. 4.3.2 Poor Accessibility to Drugs Especially in Developing Countries

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Type

      1. 5.1.1 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists

      2. 5.1.2 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    2. 5.2 By Route of Administration

      1. 5.2.1 Oral

      2. 5.2.2 Injectable

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca

      2. 6.1.2 Boehringer Ingelheim Pharmaceuticals, Inc.

      3. 6.1.3 Eli Lilly

      4. 6.1.4 GlaxoSmithKline Plc.

      5. 6.1.5 Merck Sharp & Dohme Corp

      6. 6.1.6 Novartis AG

      7. 6.1.7 Novo Nordisk

      8. 6.1.8 Sanofi

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Incretin-based Drugs Market market is studied from 2018 - 2026.

The Incretin-based Drugs Market is growing at a CAGR of 5.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

AstraZeneca , Novo Nordisk , Eli Lilly , Merck Sharp & Dohme Corp , Novartis AG are the major companies operating in Incretin-based Drugs Market .

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!